NAOV Stock Increased 26.18%: Why It Happened

By Amit Chowdhry ● Jul 30, 2021
  • The stock price of NanoVibronix Inc (NASDAQ: NAOV) increased 26.18% yesterday. This is why it happened.

The stock price of NanoVibronix Inc (NASDAQ: NAOV) – a healthcare device company that produces the UroShield and PainShield Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices – increased 26.18% yesterday, going from a previous close of $1.91 to $2.41. Investors responded positively to NanoVibronix announcing that the Therapeutic Goods Administration (TGA), The Australian Regulatory body for Therapeutic Devices, has granted approval for its UroShield to be used by patients in Australia. Plus NanoVibronix also announced that it has signed an agreement with DukeHill Healthcare Pty Ltd (DukeHill HC) to distribute its UroShield and PainShield technologies in Australia.

UroShield is an ultrasound-based product that was designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, thus reducing the incidence of catheter-associated urinary tract infections (CAUTI). UroShield is also intended to decrease pain and discomfort associated with urinary catheter use.

And PainShield is an ultrasound device that delivers a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area while keeping the level of ultrasound energy at a safe and consistent level. And its range of applications includes acute and chronic pain resolution through its many mechanisms of action. 

The product has broad applications for sports injuries. And PainShield can be used by patients at home or work or in a clinical setting and can be used even while the patient is sleeping. The patient benefits include ease of application and use, faster recovery time, high compliance, and increased safety and efficacy over existing devices that rely on higher-frequency ultrasound.

KEY QUOTES:

“Approval in Australia is yet another material milestone towards full commercialization of our products, particularly given the rigorous standards by which our UroShield device was measured by TGA. We are enthusiastic about partnering with DukeHill HC, an industry leader with significant sales resources and strong distribution capabilities in Australia. DukeHill HC have already placed their initial order validating their confidence in the technology and market potential, which we are on schedule to fulfil in the coming week, which should lay a firm foundation for immediate revenue recognition.”

“Looking ahead, PainShield, our pain management device, is also now under review by the TGA for registration and distribution in Australia as part of our strategy for global expansion.”

— Brian Murphy, Chief Executive Officer of NanoVibronix

“We anticipate a strong uptake of UroShield given its Easy to Use, Minimally Invasive, and Clinically Efficacious Platform. The UroShield has met the Australian TGA’s rigorous regulatory requirements and has been added to the official database of healthcare devices in accordance with the Regulations. This registration comes at a pivotal time for long-term catheter patients both in the Community and in Health Care Facilities (Hospital and Aged Care) who are at risk of CAUTI. UroShield enables clinicians to potentially prevent the incidence of infections in the most vulnerable patients that further complicates their care, extends the duration of hospital stays or increases the risk of readmission at a critical time for our Healthcare System. We look forward to PainShield receiving regulatory approval and joining UroShield soon.”

— Toni Hill, Managing Director of DukeHill Healthcare Pty Ltd

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.